Intuitive Surgical, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Intuitive Surgical, Inc. stock analysis ISRG overview
Bullish +75

Surgical Robotics Meets AI: Intuitive Surgical, Medtronic, and Stryker Are the Sleeper Plays of the Healthcare Boom

📈 Surgical robotics is emerging as an AI-driven sector with major moats built on data flywheels from trained surgeons.

💼 The top three companies leading this transformation are Intuitive Surgical, Medtronic, and Stryker.

🚀 All three major players are currently trading below their 2026 highs, making the investment thesis more attractive now.

💵 Stryker reported Q1 FY26 adjusted EPS of $2.60, which missed the consensus estimate of $2.98.

⚠️ Stryker's revenue came in at $6.02 billion, falling short of the $6.33 billion expected by analysts.

🛡️ CEO Kevin Lobo cited a March 11, 2026 cybersecurity incident that contributed to margin compression from 22.9% to 21.1%.

🧠 Stryker's Mako robotic franchise is integrated with power tools and accessories under its new Ortho Tech business unit.

📉 Shares of Stryker have declined by 21.3% over the past year despite maintaining full-year growth guidance.

💊 Medtronic recently received FDA clearance for its Hugo robotic-assisted surgery system, with first cases completed in February 2026.

❤️ Cardiac Ablation Solutions at Medtronic showed exceptional growth, up 80% overall due to pulsed field ablation technology.

🦴 Medtronic also secured CE Mark approval for AI-adjacent mapping navigation systems used in spinal procedures and cardiac care.

📊 Medtronic posted Q3 FY26 revenue of $9.017 billion, beating estimates with 6% organic growth driven by the Hugo system.

🧨 Non-GAAP gross margin slipped to 64.9% due to a $185 million tariff headwind affecting FY26 guidance.

💰 Intuitive Surgical reported Q1 FY26 non-GAAP EPS of $2.50, beating estimates by 18.66% for the fourth consecutive quarter.

🤖 Intuitive's installed base grew to 11,395 da Vinci systems and 1,041 Ion systems, both feeding data back into digital platforms.

⚡ 232 of the new da Vinci placements were the AI-ready da Vinci 5 units, contributing to a 16% increase in procedures.

💵 Intuitive Surgical added $7.98 billion in cash after repurchasing 2.3 million shares for $1.1 billion.

🌍 The company faces a 1.0% margin headwind from tariffs across Mexico, Germany, and China but still grew operating income by 47.95%.

📉 Intuitive Surgical shares are down 24.3% year-to-date as institutional patience is tested despite strong earnings.

🧩 Collectively, these three companies offer exposure to AI in the operating room without the high multiples of pure software stocks.

Bullish Signals
  • Intuitive Surgical reported fourth consecutive EPS beats with Q1 FY26 non-GAAP EPS of $2.50 surpassing the $2.11 estimate by 18.66%.
  • Revenue grew 22.96% year over year to $2.77 billion, primarily driven by $1.69 billion in high-margin Instruments & Accessories.
  • The installed base expanded with 11,395 da Vinci systems (up 12%) and 1,041 Ion systems (up 22%), feeding a data flywheel for surgeon analytics.
  • Adoption of new platforms accelerated significantly, with 232 da Vinci 5 units placed in the quarter versus 431 total da Vinci placements.
  • Procedure volume surged 16% for da Vinci and an impressive 39% for the Ion system, while operating income jumped 47.95%.
  • The company holds a robust $7.98 billion in cash reserves after repurchasing 2.3 million shares for $1.1 billion.
  • FY26 guidance projects strong demand with 13.5% to 15.5% da Vinci procedure growth, reflecting market confidence despite temporary tariff headwinds.
  • Medtronic beat expectations with Q3 FY26 revenue of $9.017 billion and non-GAAP EPS of $1.36 surpassing the consensus.
  • Cardiac Ablation Solutions demonstrated explosive growth, driving revenue up 80% overall and 137% in the United States via pulsed field ablation.
  • Medtronic secured regulatory milestones including FDA clearance for the Hugo system with first cases completed in February 2026, and CE Mark for Sphere-360 mapping catheter.
  • CEO Geoff Martha highlighted strong organic revenue growth of 6% in Q3, which exceeded guidance and signaled an exciting expansion phase.
  • Despite sector drawdowns, Medtronic's forward P/E of 14x and analyst target of $108 present the stock as attractively priced.
  • Stryker CEO Kevin Lobo expressed confidence in recovering quickly from the March 11, 2026 cybersecurity incident while maintaining full-year guidance.
  • Key growth categories remain intact at Stryker with knees growing 4.7% and hips growing 3.7% under their Mako robotic platforms.
  • Stryker committed to sustained organic sales growth of 8.0% to 9.5% and adjusted EPS between $14.90 to $15.10 for the full year.
Risk Factors
  • Stryker missed Q1 FY26 adjusted EPS estimates ($2.60 vs $2.98) and revenue expectations ($6.02B vs $6.33B).
  • Stryker's adjusted operating margin compressed to 21.1% from 22.9% due to a March 11, 2026 cybersecurity incident and $118 million in structural optimization charges.
  • Intuitive Surgical faces tariff exposure across Mexico, Germany, and China embedded as a 1.0% margin headwind.
  • Medtronic is dealing with a $185 million tariff headwind that is baked into FY26 guidance.
  • Medtronic's non-GAAP gross margin slipped to 64.9% from 66.6%, indicating potential profitability pressure.
  • Intuitive Surgical's shares are down 24.3% year to date, putting institutional patience under stress despite insider accumulation.
  • The market currently treats the AI-enabled data flywheel thesis for surgical robotics as immaterial.
  • Stryker faces execution risk where Mako revenue is bundled, preventing investors from isolating the growth of their AI orthopedics flywheel.
Full Analysis
Intuitive Surgical (ISRG), Medtronic (MDT), and Stryker (SYK) are identified as key players where surgical robotics integrates with artificial intelligence capabilities. Intuitive Surgical reported Q1 FY26 non-GAAP EPS of $2.50, beating estimates by 18.66%, with revenue reaching $2.77 billion. The company's installed base of da Vinci systems (11,395 units) and Ion systems continues to expand, providing data for analytics platforms. While tariff headwinds from Mexico, Germany, and China impact margins by approximately 1.0%, the company maintains strong cash reserves and guidance suggests continued growth in procedure volumes for both its core da Vinci line and newer Ion system. Medtronic achieved a significant milestone with FDA clearance for the Hugo robotic-assisted surgery system, enabling first cases in February 2026. Its Q3 FY26 revenue of $9.017 billion exceeded analyst expectations, driven notably by an 80% increase in overall Pulmonary Field Ablation solutions revenue. The company also expanded its portfolio with FDA clearance for the Stealth AXiS Surgical System for spinal procedures and a CE Mark for the Sphere-360 mapping catheter. Despite a non-GAAP gross margin slip to 64.9% due to $185 million in tariff headwinds, CEO Geoff Martha highlighted strong organic revenue growth of 6%, with shares trading at an attractive forward P/E of 14x despite a significant year-to-date drawdown. Stryker faced a mixed quarter where Q1 FY26 adjusted EPS of $2.60 and revenue of $6.02 billion both missed consensus estimates due to $118 million in structural optimization charges linked to a March 11, 2026 cybersecurity incident. Operating margins were compressed to 21.1% from the prior year's 22.9%. However, the company maintains its full-year guidance for organic sales growth of 8.0% to 9.5% and adjusted EPS between $14.90 and $15.10. Growth in Mako-tethered orthopedic categories remains steady with knees growing 4.7% and hips growing 3.7%. Collectively, these three companies represent exposure to the AI-driven surgical robotics flywheel with durable moats built on installed bases, though their current market valuations reflect concerns regarding tariffs, cybersecurity events, and temporary margin pressures rather than a lack of fundamental strength.